Canaccord Genuity Maintains a 'Buy' on Zalicus (ZLCS); Q3/11 Update: Synavive Ph 2 Enrollment on Track
Tweet
Share
E-mailGet Alerts ZLCS Hot Sheet
Price: $1.18 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Phase 2 drug for RA, with major market potential in various conditions treated with low-dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Phase 1b ready Z160, a novel calcium channel blocker."
For more ratings news on Zalicus click here and for the rating history of Zalicus click here.
Shares of Zalicus closed at $1.29 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Phase 2 drug for RA, with major market potential in various conditions treated with low-dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Phase 1b ready Z160, a novel calcium channel blocker."
For more ratings news on Zalicus click here and for the rating history of Zalicus click here.
Shares of Zalicus closed at $1.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- ICICI Securities Downgrades Manappuram Finance Ltd (MGFL:IN) to Hold (3)
- ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
